Investigational Drug Information for DAS181
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for DAS181?
DAS181 is an investigational drug.
There have been 14 clinical trials for DAS181.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 23rd 2019.
The most common disease conditions in clinical trials are Influenza, Human, COVID-19, and Paramyxoviridae Infections. The leading clinical trial sponsors are Ansun Biopharma, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and National Institutes of Health (NIH).
There are three US patents protecting this investigational drug and thirty-nine international patents.
Summary for DAS181
| US Patents | 3 |
| International Patents | 39 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-05-23) |
| Vendors | 0 |
Recent Clinical Trials for DAS181
| Title | Sponsor | Phase |
|---|---|---|
| DAS181 for STOP COVID-19 | Ansun Biopharma, Inc. | Phase 2/Phase 3 |
| DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) | Ansun Biopharma, Inc. | Phase 2 |
| DAS181 for Severe COVID-19: Compassionate Use | Ansun Biopharma, Inc. | N/A |
Clinical Trial Summary for DAS181
Top disease conditions for DAS181
Top clinical trial sponsors for DAS181
US Patents for DAS181
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| DAS181 | See Plans and Pricing | Treatment of infection by human enterovirus D68 | Ansun Biopharma, Inc. (San Diego, CA) | See Plans and Pricing |
| DAS181 | See Plans and Pricing | 2'-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (Foster City, CA) | See Plans and Pricing |
| DAS181 | See Plans and Pricing | Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture | Ansun Biopharma, Inc. (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for DAS181
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| DAS181 | World Intellectual Property Organization (WIPO) | WO2016044656 | 2034-09-17 | See Plans and Pricing |
| DAS181 | Australia | AU2013232378 | 2032-03-13 | See Plans and Pricing |
| DAS181 | Australia | AU2017279590 | 2032-03-13 | See Plans and Pricing |
| DAS181 | Brazil | BR122016003311 | 2032-03-13 | See Plans and Pricing |
| DAS181 | Canada | CA2866381 | 2032-03-13 | See Plans and Pricing |
| DAS181 | China | CN104185638 | 2032-03-13 | See Plans and Pricing |
| DAS181 | China | CN106749272 | 2032-03-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
